Eli Lilly's incretin manufacturing facility at Research Triangle Park in North Carolina
July 23, 2024 10:15 AM EDTUpdated July 25, 04:16 PM
Pharma
In Focus
Manufacturing

The obe­si­ty drug race is be­ing fought on the man­u­fac­tur­ing floor as GLP-1 ri­vals make plans to catch lead­ers

Anna Brown

News Reporter

Ever since the weight loss drug craze cre­at­ed near-un­prece­dent­ed de­mand, the first two com­pa­nies to mar­ket have been do­ing every­thing they can to meet it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Out­look's shares crash as wet AMD drug flunks Phase 3 test

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times